Hilton Worldwide vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Global hotel company with 7,700+ properties, 1.2M rooms, 22 brands; $11.2B FY2024 revenue; 180M+ Hilton Honors members; 100% asset-light; 490,000-room development pipeline.
About
Hilton Worldwide Holdings is one of the world's largest and most recognized hotel companies, founded in 1919 by Conrad Hilton in Cisco, Texas and now headquartered in McLean, Virginia, trading on NYSE (HLT). The company manages approximately 7,700 properties with 1.2 million rooms across 22 brands in 126 countries, ranging from the ultra-luxury Waldorf Astoria Collection to extended-stay Home2 Suites by Hilton, all operating under Hilton's 100% asset-light franchise and management model. For FY2024, Hilton generated approximately $11.2 billion in revenues under CEO Christopher Nassetta, with Hilton Honors loyalty membership exceeding 180 million members—the world's largest hotel loyalty program—driving direct booking rates above 70% and reducing dependency on third-party online travel agencies.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.